INTRODUCTION
NSCLC
LUNG CANCER, PROLIFERATION, NSCLC
Established small‐molecule tyrosine kinase inhibitors (TKIs) target epidermal growth factor receptor (EGFR) and are effective in non‐small cell lung cancer (NSCLC) patients with activating and sensitizing EGFR mutations. These mutations are localized in exons 18–21 of the AXL is a member of the TAM (TYRO3, AXL, and MERTK) family of receptor tyrosine kinases and, along with its ligand growth arrest‐specific gene 6 (GAS6), plays an important role in promoting growth, survival, and proliferation in both normal and malignant cells.